MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

NCT05780463 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

485

Enrollment

NIH

Sponsor class

Conditions

COVID-19

Interventions

DRUG: MP0420
DRUG: Placebo
BIOLOGICAL: Remdesivir

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]